Annexon (NASDAQ:ANNX) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Annexon (NASDAQ:ANNX) in a report published on Friday,Benzinga reports.

Other equities analysts have also recently issued reports about the company. Needham & Company LLC restated a “buy” rating and set a $16.00 price objective on shares of Annexon in a research note on Friday. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Annexon in a report on Friday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $15.80.

Annexon Stock Down 3.3 %

Shares of Annexon stock opened at $6.12 on Friday. Annexon has a 52 week low of $2.27 and a 52 week high of $8.40. The business has a 50 day moving average price of $6.91 and a 200-day moving average price of $5.92. The company has a market cap of $646.58 million, a PE ratio of -5.83 and a beta of 1.23.

Insider Transactions at Annexon

In related news, EVP Ted Yednock sold 5,500 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $5.64, for a total value of $31,020.00. Following the sale, the executive vice president now directly owns 10,000 shares in the company, valued at approximately $56,400. The trade was a 35.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 20,908 shares of company stock worth $135,768 in the last quarter. Insiders own 12.67% of the company’s stock.

Institutional Investors Weigh In On Annexon

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. ProShare Advisors LLC purchased a new position in shares of Annexon in the first quarter valued at $87,000. Vanguard Group Inc. grew its holdings in Annexon by 96.4% during the 1st quarter. Vanguard Group Inc. now owns 3,747,655 shares of the company’s stock valued at $26,871,000 after buying an additional 1,839,329 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Annexon by 9.6% during the 1st quarter. Acadian Asset Management LLC now owns 957,993 shares of the company’s stock valued at $6,867,000 after buying an additional 83,969 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Annexon by 78.2% in the first quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock worth $48,000 after buying an additional 2,949 shares in the last quarter. Finally, American International Group Inc. boosted its position in shares of Annexon by 46.3% in the first quarter. American International Group Inc. now owns 33,197 shares of the company’s stock valued at $238,000 after acquiring an additional 10,510 shares during the period.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.